: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Leukemia

Free Subscription

Articles published in Leuk Lymphoma
Retrieve available abstracts of 460 articles:
HTML format

Single Articles

May 2024

HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
PubMed Abstract available

ROGERS KA, Thompson PA
Pairing obinutuzumab with venetoclax in relapsed CLL.
Leuk Lymphoma. 2024;65:543-545.
PubMed

GARCIAZ S, Berton G, Hospital MA, Guille A, et al
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
Leuk Lymphoma. 2024;65:700-703.
PubMed

OKABE S, Moriyama M, Gotoh A
Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
Leuk Lymphoma. 2024;65:696-699.
PubMed

FATIMA N, Shen Y, Crassini K, Burling O, et al
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
Leuk Lymphoma. 2024;65:585-597.
PubMed Abstract available

April 2024

NESR G, Claudiani S, Milojkovic D, Innes A, et al
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
PubMed Abstract available

STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
Challenges in management of older patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
PubMed Abstract available

BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
PubMed Abstract available

FLECK C, Karabinos A, Cook A, Moore DC, et al
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
PubMed

TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
PubMed

STEIN EM, Fathi AT, Harb WA, Colak G, et al
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Leuk Lymphoma. 2024;65:503-510.
PubMed Abstract available

PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
Leuk Lymphoma. 2024;65:449-459.
PubMed Abstract available

ALDOSS I, Clark MC, Wang X, Forman SJ, et al
Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
Leuk Lymphoma. 2024;65:440-448.
PubMed Abstract available

March 2024

CORTES J, Jonas BA, Schiller G, Mims A, et al
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
PubMed Abstract available

MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
PubMed

ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
PubMed

LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
RAD21 mutations in acute myeloid leukemia.
Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
PubMed Abstract available

ZHU J, Xu M, Ru Y, Gong H, et al
Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
PubMed Abstract available

February 2024

NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
PubMed

HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
PubMed Abstract available

TANG K, Lipton JH
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
PubMed Abstract available

YARED JA, Lee TY, Cooke CE, Johnson A, et al
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
PubMed Abstract available

EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
Leuk Lymphoma. 2024;65:199-208.
PubMed Abstract available

JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
Leuk Lymphoma. 2024;65:209-218.
PubMed Abstract available

January 2024

LEI MM, Sorial MN, Lou U, Yu M, et al
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
PubMed Abstract available

NASR AA, Fund X, Barreau S, Desterke C, et al
BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
PubMed

TADMOR T, Levy Yurkovski I
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
PubMed

FU S, Alhaj Z, Huynh D
Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
PubMed

BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
PubMed Abstract available

NGO D, Tinajero J, Li S, Palmer J, et al
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
PubMed Abstract available

December 2023

SALTER B, Radford JM, Berg T, Leber B, et al
The successful management of acute promyelocytic leukemia during pregnancy: a case report.
Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
PubMed

MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
PubMed

WANG L, Gao L, Liang Z, Cen X, et al
Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
PubMed Abstract available

JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
PubMed Abstract available

ZHANG F, Hu GH, Zhang LP, Xu LP, et al
Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
PubMed

MURTON A, Forsyth C, Ross DM, Grigg A, et al
Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
Leuk Lymphoma. 2023;64:2018-2025.
PubMed Abstract available

STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
Leuk Lymphoma. 2023;64:1992-2001.
PubMed Abstract available

REDD RA, Ford J, Lei M, Abramson JS, et al
Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
Leuk Lymphoma. 2023;64:2296-2305.
PubMed Abstract available

YANG T, Mahmood N, Goldberg B, Cevallos J, et al
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
Leuk Lymphoma. 2023;64:2338-2342.
PubMed

TOMASULO E, Paul S, Mu R, Tian X, et al
Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Leuk Lymphoma. 2023;64:2306-2315.
PubMed Abstract available

SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
Leuk Lymphoma. 2023;64:2333-2337.
PubMed

ZHANG X, Wang T, Zhang Y, Wang F, et al
Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
Leuk Lymphoma. 2023;64:2133-2139.
PubMed Abstract available

November 2023

LAI X, Xiao J, Wang T, Hou C, et al
Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
PubMed Abstract available

OU J, Xu X, Deng S, Liang H, et al
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
PubMed Abstract available

FATIMA N, Best OG, Belov L, Christopherson RI, et al
The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
PubMed Abstract available

KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
PubMed Abstract available

SASTOW D, Tatarian J, Salib C, Lin TL, et al
Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
PubMed

FRATER JL
Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
PubMed

SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
PubMed Abstract available

TRINQUAND A, Betts DR, Harte S, Sills A, et al
Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
PubMed

RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
Role of IL8 in myeloid malignancies.
Leuk Lymphoma. 2023;64:1742-1751.
PubMed Abstract available

ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
PubMed

October 2023

MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
PubMed Abstract available

CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
PubMed Abstract available

HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
PubMed Abstract available

LIAO C, Nie J, Xu XJ, Zhang JY, et al
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
PubMed Abstract available

ZAHID MF, Kainthla R
Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
PubMed

GAUT D, Oliai C, Boiarsky J, Zhang S, et al
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
PubMed Abstract available

YASU T, Gando Y, Shirota M, Kosugi N, et al
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
PubMed

SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
Leuk Lymphoma. 2023;64:1689-1694.
PubMed Abstract available

CHAI J, Choudhuri J, Wang Q, Fang Y, et al
Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Leuk Lymphoma. 2023;64:1662-1672.
PubMed Abstract available

September 2023

LI L, Zhang R, Cao W, Bian Z, et al
Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
PubMed Abstract available

HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
PubMed Abstract available

LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
PubMed Abstract available

IELO C, Scalzulli E, Carmosino I, Pepe S, et al
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
PubMed Abstract available

LA J, Lee MH, Brophy MT, Do NV, et al
Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
PubMed Abstract available

BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
PubMed Abstract available

NEDUMANNIL R, Batterham E, Harding E, Ritchie D, et al
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia.
Leuk Lymphoma. 2023 Sep 1:1-10. doi: 10.1080/10428194.2023.2251071.
PubMed Abstract available

August 2023

COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Leuk Lymphoma. 2023 Aug 25:1-4. doi: 10.1080/10428194.2023.2247511.
PubMed

SASTOW D, Tatarian J, Riazat-Kesh YJRA, Farina K, et al
Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.
Leuk Lymphoma. 2023 Aug 17:1-6. doi: 10.1080/10428194.2023.2248331.
PubMed Abstract available

DHARIWAL N, Roy Moulik N, Smriti V, Dhamne C, et al
Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Aug 11:1-10. doi: 10.1080/10428194.2023.2245093.
PubMed Abstract available

AGHEL N, Gustafson D, Delgado D, Atenafu EG, et al
High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Leuk Lymphoma. 2023 Aug 9:1-10. doi: 10.1080/10428194.2023.2242990.
PubMed Abstract available

SCAMUFFA MC, Latagliata R, Carmosino I, Di Veroli A, et al
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents.
Leuk Lymphoma. 2023 Aug 8:1-7. doi: 10.1080/10428194.2023.2239407.
PubMed Abstract available

BECERRIL-RICO J, Delgado-Montes YA, Ortiz-Sanchez E
Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
Leuk Lymphoma. 2023 Aug 7:1-10. doi: 10.1080/10428194.2023.2243357.
PubMed Abstract available

DE MATOS RRC, Ferreira GM, Bonecker S, Rouxinol M, et al
BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia.
Leuk Lymphoma. 2023 Aug 7:1-5. doi: 10.1080/10428194.2023.2243532.
PubMed

ARIBI A, Salhotra A, Afkhami M, Munteanu A, et al
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Leuk Lymphoma. 2023 Aug 3:1-11. doi: 10.1080/10428194.2023.2241096.
PubMed Abstract available

WASIFUDDIN M, Ilerhunmwuwa NP, Becerra H, Wang JC, et al
Characteristics and survival outcomes of patients with T cell prolymphocytic leukemia in the United States: 2011-2020 analysis of the SEER database.
Leuk Lymphoma. 2023 Aug 2:1-3. doi: 10.1080/10428194.2023.2243354.
PubMed

LOCATELLI F, Shah B, Thomas T, Velasco K, et al
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review.
Leuk Lymphoma. 2023 Aug 1:1-19. doi: 10.1080/10428194.2023.2232496.
PubMed Abstract available

July 2023

JEFFREY A, Presgrave P, Walsh CA, Sinn J, et al
Successful treatment of acute lymphoblastic leukemia (ALL) during pregnancy using a pediatric-based protocol incorporating pegylated asparaginase.
Leuk Lymphoma. 2023 Jul 30:1-4. doi: 10.1080/10428194.2023.2239406.
PubMed

DUNN-VALADEZ S, Bathini S, Purdy KE, Bachiashvili K, et al
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Leuk Lymphoma. 2023 Jul 26:1-8. doi: 10.1080/10428194.2023.2234529.
PubMed Abstract available

MUFFLY L, Young C, Feng Q, Nimke D, et al
Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Leuk Lymphoma. 2023 Jul 24:1-8. doi: 10.1080/10428194.2023.2235044.
PubMed Abstract available

BABAKHANLOU R, DiNardo C, Borthakur G
IDH2 mutations in acute myeloid leukemia.
Leuk Lymphoma. 2023 Jul 18:1-9. doi: 10.1080/10428194.2023.2237153.
PubMed Abstract available

ARRIBAS I, Maluquer C, Pomares H, Carro I, et al
B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
Leuk Lymphoma. 2023 Jul 17:1-5. doi: 10.1080/10428194.2023.2234527.
PubMed

CARDINALI D, Beldinanzi M, Ansuinelli M, Elia L, et al
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Leuk Lymphoma. 2023 Jul 15:1-4. doi: 10.1080/10428194.2023.2235450.
PubMed

ARGUELLO-TOMAS M, Albiol N, Jara P, Garcia-Cadenas I, et al
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
Leuk Lymphoma. 2023 Jul 15:1-7. doi: 10.1080/10428194.2023.2232489.
PubMed Abstract available

MARAGLINO AME, Amato V, Sammassimo S, Gigli F, et al
Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.
Leuk Lymphoma. 2023 Jul 14:1-4. doi: 10.1080/10428194.2023.2234524.
PubMed

IAQUINTA G, Scalzulli E, Angeloni S, Carmosino I, et al
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases.
Leuk Lymphoma. 2023 Jul 12:1-3. doi: 10.1080/10428194.2023.2232495.
PubMed Abstract available

CHEN H, Zhao X, Pan W, Xiao H, et al
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation.
Leuk Lymphoma. 2023 Jul 10:1-8. doi: 10.1080/10428194.2023.2232493.
PubMed Abstract available

ZHANG Y, Ding Y, Zhang R, Zhang L, et al
Aberrant expression of CD5 in adult acute myeloid leukemia belonged to AML-MR, may represent a uniquely aggressive subcategory.
Leuk Lymphoma. 2023 Jul 3:1-4. doi: 10.1080/10428194.2023.2230332.
PubMed

GUASTAFIERRO V, Ubezio M, Manes N, Milanesi C, et al
CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
Leuk Lymphoma. 2023 Jul 3:1-8. doi: 10.1080/10428194.2023.2227750.
PubMed Abstract available

June 2023

LUTTWAK E, Noy A, Seshan V, Saltzman LA, et al
The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.
Leuk Lymphoma. 2023 Jun 29:1-3. doi: 10.1080/10428194.2023.2227749.
PubMed

FEI F, Stehr H, Zehnder JL
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience.
Leuk Lymphoma. 2023 Jun 17:1-9. doi: 10.1080/10428194.2023.2220450.
PubMed Abstract available

PATEL SA
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.
Leuk Lymphoma. 2023 Jun 16:1-11. doi: 10.1080/10428194.2023.2224473.
PubMed Abstract available

ROCCOGRANDI LM, Lovell AR, Ferrajoli A, Thompson PA, et al
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Leuk Lymphoma. 2023 Jun 15:1-8. doi: 10.1080/10428194.2023.2223740.
PubMed Abstract available

PARISI R, Cowen EA, Gu S, Dusza S, et al
Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
Leuk Lymphoma. 2023 Jun 12:1-5. doi: 10.1080/10428194.2023.2221756.
PubMed

CELLA D, Kelly K, de la Motte A, Toublan F, et al
The experience of patients with acute myeloid leukemia in remission post-transplant.
Leuk Lymphoma. 2023 Jun 8:1-10. doi: 10.1080/10428194.2023.2210711.
PubMed Abstract available

CHEN H, Zhang Y, Jiang Y, Lin L, et al
Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.
Leuk Lymphoma. 2023 Jun 6:1-7. doi: 10.1080/10428194.2023.2217711.
PubMed Abstract available

WANG Y, Tang X, Zhu Y, Yang XX, et al
Role of interleukins in acute myeloid leukemia.
Leuk Lymphoma. 2023 Jun 1:1-14. doi: 10.1080/10428194.2023.2218508.
PubMed Abstract available

MOLENDIJK EBD, van der Velden WJFM, Aarntzen EHJG, Coolen JPM, et al
Emergence of invasive infections with Magnusiomyces species in AML patients in a single center: a possible relationship with echinocandin prophylaxis.
Leuk Lymphoma. 2023;64:1199-1203.
PubMed

VENUGOPAL S, Sekeres MA
Raising the bar for lower-risk myelodysplastic syndromes.
Leuk Lymphoma. 2023;64:1082-1091.
PubMed Abstract available

May 2023

BRAVO J, Baltasar Tello P, Gonzalez Garcia E, Rios Herranz E, et al
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Leuk Lymphoma. 2023 May 31:1-14. doi: 10.1080/10428194.2023.2216327.
PubMed Abstract available

SHARMAN JP, Miranda P, Roos J, Emeribe U, et al
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 May 23:1-10. doi: 10.1080/10428194.2023.2212433.
PubMed Abstract available

MURATORE E, Belotti T, Gottardi F, Sagramoso C, et al
Miliary leukemia cutis as extramedullary relapse of KMT2A rearranged pediatric AML.
Leuk Lymphoma. 2023 May 23:1-3. doi: 10.1080/10428194.2023.2214650.
PubMed

TARIQ H, Shetty S
Post PARP inhibitor therapy-related acute megakaryoblastic leukemia in a patient with germline BRCA1-mutated high-grade serous ovarian carcinoma.
Leuk Lymphoma. 2023 May 19:1-5. doi: 10.1080/10428194.2023.2213367.
PubMed

YIMAZ B, Koc A, Dogru O, Tufan Tas B, et al
The results of the modified St Jude Total Therapy XV Protocol in the treatment of low- and middle-income children with acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 May 10:1-13. doi: 10.1080/10428194.2023.2205976.
PubMed Abstract available

ANTONY ML, Chang D, Noble-Orcutt KE, Kay A, et al
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state.
Leuk Lymphoma. 2023 May 10:1-13. doi: 10.1080/10428194.2023.2207698.
PubMed Abstract available

LEBLANC TW
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies.
Leuk Lymphoma. 2023;64:910-912.
PubMed

RITCHIE EK, Cella D, Fabbiano F, Pigneux A, et al
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML.
Leuk Lymphoma. 2023;64:938-950.
PubMed Abstract available

RAMIA DE CAP M, Wu LP, Hirt C, Pihan GA, et al
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.
Leuk Lymphoma. 2023;64:972-980.
PubMed Abstract available

KOPMAR NE, Gooley T, Curley N, Russell K, et al
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Leuk Lymphoma. 2023;64:1057-1059.
PubMed

MCGHIE A, Lee J, Ferrajoli A, DiPippo AJ, et al
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center.
Leuk Lymphoma. 2023;64:1050-1053.
PubMed

April 2023

KHELIFI RS, Huang SJ, Savage KJ, Villa D, et al
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada.
Leuk Lymphoma. 2023 Apr 22:1-10. doi: 10.1080/10428194.2023.2199340.
PubMed Abstract available

HU CC, Subramanian R, Grigg A
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft.
Leuk Lymphoma. 2023 Apr 20:1-8. doi: 10.1080/10428194.2023.2203289.
PubMed Abstract available

WALCHECK MT, Nukaya M, Ranheim EA, Matkowskyj KA, et al
Pdx1 expression in hematopoietic cells activates Kras-mutation to drive leukemia in KC (Pdx1-Cre; LSL-Kras(G12D/+)) mice.
Leuk Lymphoma. 2023 Apr 20:1-11. doi: 10.1080/10428194.2023.2202788.
PubMed Abstract available

MEHYAR LS, Hartog L, Kahwash SB, Abu-Arja R, et al
Long term survivor of MOZ-p300 therapy-related acute myeloid leukemia after matched unrelated donor bone marrow transplantation.
Leuk Lymphoma. 2023 Apr 20:1-4. doi: 10.1080/10428194.2023.2203287.
PubMed

LIU C, Zhang X, Mao L, Qian J, et al
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases.
Leuk Lymphoma. 2023 Apr 17:1-4. doi: 10.1080/10428194.2023.2197534.
PubMed

BRIX N, Kessel C, Foell D, Hasle H, et al
Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value.
Leuk Lymphoma. 2023 Apr 17:1-9. doi: 10.1080/10428194.2023.2193855.
PubMed Abstract available

HOFF FW, Patel PA, Belli AJ, Hansen E, et al
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
Leuk Lymphoma. 2023 Apr 13:1-6. doi: 10.1080/10428194.2023.2197090.
PubMed Abstract available

DECLERCK C, Giltat A, Boutemy R, Brisset-Dheilly M, et al
Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.
Leuk Lymphoma. 2023 Apr 13:1-4. doi: 10.1080/10428194.2023.2196595.
PubMed

MUSTAFA ALI MK, Williams MT, Corley EM, AlKaabba F, et al
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.
Leuk Lymphoma. 2023 Apr 12:1-10. doi: 10.1080/10428194.2023.2190432.
PubMed Abstract available

ALLSUP D, Molica S
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report.
Leuk Lymphoma. 2023 Apr 11:1-3. doi: 10.1080/10428194.2023.2199341.
PubMed

ALDOSS I, Gu Z, Afkhami M, Mokhtari S, et al
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
Leuk Lymphoma. 2023 Apr 6:1-10. doi: 10.1080/10428194.2023.2197538.
PubMed Abstract available

ROBAK T, Kasprzak JD, Jesionek-Kupnicka D, Soin M, et al
Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis.
Leuk Lymphoma. 2023;64:884-888.
PubMed

YEOH ZH, Wei A
Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease.
Leuk Lymphoma. 2023;64:757-760.
PubMed

KLEINSTERN G, Slager SL
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.
Leuk Lymphoma. 2023;64:788-798.
PubMed Abstract available

March 2023

EYRE TA, Hess LM, Sugihara T, He D, et al
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
Leuk Lymphoma. 2023 Mar 29:1-12. doi: 10.1080/10428194.2023.2190436.
PubMed Abstract available

XIAO J, Xie J, Zhou B, Liu Y, et al
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
Leuk Lymphoma. 2023 Mar 24:1-11. doi: 10.1080/10428194.2023.2190433.
PubMed Abstract available

SALVARIS RT, Allanson B, Cheah CY
Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia.
Leuk Lymphoma. 2023 Mar 24:1-5. doi: 10.1080/10428194.2023.2192316.
PubMed

AMMAD UD DIN M, Saeed H, Shahzad M, Liaqat H, et al
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia.
Leuk Lymphoma. 2023 Mar 20:1-5. doi: 10.1080/10428194.2023.2190435.
PubMed

HARDELL L, Carlberg M, Nordstrom M, Eriksson M, et al
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma- pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia.
Leuk Lymphoma. 2023 Mar 20:1-8. doi: 10.1080/10428194.2023.2190434.
PubMed Abstract available

CASSADAY RD, Zarling LC, Garcia KA, Sala-Torra O, et al
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Mar 20:1-11. doi: 10.1080/10428194.2023.2189803.
PubMed Abstract available

TADMOR T, Melamed G, Patalon T, Alapi H, et al
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.
Leuk Lymphoma. 2023 Mar 13:1-3. doi: 10.1080/10428194.2023.2183732.
PubMed

PASSERINI M, Ratishvili T, Monroe JM, Temesgen Z, et al
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 Mar 12:1-10. doi: 10.1080/10428194.2023.2183730.
PubMed Abstract available

ROBAK T
Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?
Leuk Lymphoma. 2023 Mar 10:1-3. doi: 10.1080/10428194.2023.2188103.
PubMed

ZHANG MY, Othus M, Shaw C, Schonhoff KG, et al
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
Leuk Lymphoma. 2023 Mar 8:1-7. doi: 10.1080/10428194.2023.2186732.
PubMed Abstract available

MAJUMDAR S, Sharma N, Sengar M, Thorat J, et al
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
Leuk Lymphoma. 2023 Mar 8:1-11. doi: 10.1080/10428194.2023.2167491.
PubMed Abstract available

COLTOFF A
Leukocytosis and MPNs: Where do we stand?
Leuk Lymphoma. 2023;64:564-572.
PubMed Abstract available

PAUL P, Stussi G, Bruscaggin A, Rossi D, et al
Genetics and epigenetics of CLL.
Leuk Lymphoma. 2023;64:551-563.
PubMed Abstract available

WANG C, Sallman DA
Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Leuk Lymphoma. 2023;64:511-524.
PubMed Abstract available

FELD J, Tremblay D, Navada SC, Silverman LR, et al
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Leuk Lymphoma. 2023;64:525-539.
PubMed Abstract available

February 2023

ARIBI A, Salhotra A, Ball B, Stein A, et al
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Leuk Lymphoma. 2023 Feb 27:1-3. doi: 10.1080/10428194.2023.2179361.
PubMed

MOLICA S, Giannarelli D
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis.
Leuk Lymphoma. 2023 Feb 27:1-4. doi: 10.1080/10428194.2023.2181656.
PubMed

CHOQUETTE T, Henson ES, Yang X, Johnston JB, et al
A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).
Leuk Lymphoma. 2023 Feb 19:1-13. doi: 10.1080/10428194.2023.2171729.
PubMed Abstract available

XU W, Yang S, Zhou K, Pan L, et al
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Leuk Lymphoma. 2023 Feb 17:1-5. doi: 10.1080/10428194.2022.2164692.
PubMed

SANDLEY M, Angus J
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Leuk Lymphoma. 2023 Feb 13:1-12. doi: 10.1080/10428194.2023.2171267.
PubMed Abstract available

OWATARI S, Tokunaga M, Nakamura D, Uozumi K, et al
A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.
Leuk Lymphoma. 2023 Feb 10:1-9. doi: 10.1080/10428194.2023.2173524.
PubMed Abstract available

ARGYROPOULOS KV, Aypar U, Ewalt MD, Roshal M, et al
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype.
Leuk Lymphoma. 2023 Feb 7:1-4. doi: 10.1080/10428194.2022.2161819.
PubMed

SANBER K, Ye K, Tsai HL, Newman M, et al
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Leuk Lymphoma. 2023 Feb 6:1-10. doi: 10.1080/10428194.2023.2173523.
PubMed Abstract available

KUTSCH N, Holmes EE, Robrecht S, Schuler G, et al
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Leuk Lymphoma. 2023;64:478-482.
PubMed

January 2023

PENA C, Riva E, Schutz N, Ramirez A, et al
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
Leuk Lymphoma. 2023 Jan 25:1-6. doi: 10.1080/10428194.2023.2171266.
PubMed Abstract available

ZHANG S, Feng R, Bai J, Ning S, et al
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo.
Leuk Lymphoma. 2023 Jan 19:1-12. doi: 10.1080/10428194.2023.2169045.
PubMed Abstract available

BATALLER A, Haddad FG, Issa GC, Sasaki K, et al
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.
Leuk Lymphoma. 2023 Jan 19:1-4. doi: 10.1080/10428194.2023.2165395.
PubMed

WANG J, Sun K, Chen WM, Wang X, et al
The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Jan 15:1-9. doi: 10.1080/10428194.2022.2164193.
PubMed Abstract available

DHAKAL P, Lyden E, Joshi U, Pyakuryal A, et al
Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients.
Leuk Lymphoma. 2023 Jan 11:1-7. doi: 10.1080/10428194.2023.2165394.
PubMed Abstract available

AQIL B, Kaur A, Ramos J, Sukhanova M, et al
Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL/SLL treated by ibrutinib.
Leuk Lymphoma. 2023;64:242-245.
PubMed

SHAO X, Meng X, Yang H, Wang X, et al
IFN-gamma enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway.
Leuk Lymphoma. 2023;64:71-78.
PubMed Abstract available

December 2022

YASU T, Sakurai K, Hoshino M, Akazawa M, et al
Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study.
Leuk Lymphoma. 2022 Dec 28:1-4. doi: 10.1080/10428194.2022.2161305.
PubMed

CHIARETTI S, Taherinasab A, Della Starza I, Canichella M, et al
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
Leuk Lymphoma. 2022 Dec 19:1-4. doi: 10.1080/10428194.2022.2148217.
PubMed

ASSOULINE S, Michaelis LC, Othus M, Hay AE, et al
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of
Leuk Lymphoma. 2022 Dec 14:1-5. doi: 10.1080/10428194.2022.2148212.
PubMed

BANTILAN KS, Kay NE, Parikh SA, Rabe KG, et al
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.
Leuk Lymphoma. 2022 Dec 12:1-12. doi: 10.1080/10428194.2022.2148218.
PubMed Abstract available

BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.
Leuk Lymphoma. 2022 Dec 9:1-8. doi: 10.1080/10428194.2022.2140288.
PubMed Abstract available

HYLAND KA, Eisel SL, Hoogland AI, Root JC, et al
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.
Leuk Lymphoma. 2022 Dec 7:1-9. doi: 10.1080/10428194.2022.2148208.
PubMed Abstract available

WIERDA WG, Kipps TJ, Al-Sawaf O, Chyla B, et al
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Leuk Lymphoma. 2022;63:2765-2784.
PubMed Abstract available

HAYNES J, Jackson M, Smugar SS
Increased risk of severe cutaneous adverse reactions when cladribine is used together with other medications with a propensity for skin reactions.
Leuk Lymphoma. 2022;63:2965-2974.
PubMed Abstract available

TANG C, Shen Y, Soosapilla A, Mulligan SP, et al
Monoclonal B-cell Lymphocytosis - a review of diagnostic criteria, biology, natural history, and clinical management.
Leuk Lymphoma. 2022;63:2795-2806.
PubMed Abstract available

ABBAS HA, Ayoub E, Sun H, Kanagal-Shamanna R, et al
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment.
Leuk Lymphoma. 2022;63:3105-3116.
PubMed Abstract available

LONTOS K, Tsagianni A, Agha M, Raptis A, et al
A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.
Leuk Lymphoma. 2022;63:3257-3260.
PubMed

CANON A, Roy L, Chevalier X, Giraudier S, et al
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?
Leuk Lymphoma. 2022;63:3175-3180.
PubMed Abstract available

AMANAM I, Ngo D, Pullarkat V, Aldoss I, et al
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis.
Leuk Lymphoma. 2022;63:3268-3270.
PubMed

PETHUSAMY K, Seethy A, Dhar R, Karmakar A, et al
Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.
Leuk Lymphoma. 2022;63:3426-3432.
PubMed Abstract available

November 2022

MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
PubMed Abstract available

ECTOR GICG, Geelen IGP, Dinmohamed AG, Hoogendoorn M, et al
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
Leuk Lymphoma. 2022 Nov 11:1-9. doi: 10.1080/10428194.2022.2142055.
PubMed Abstract available

FENG X, Zheng Y, Xu J
Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia.
Leuk Lymphoma. 2022 Nov 9:1-4. doi: 10.1080/10428194.2022.2142052.
PubMed

CHEN WONGWORAWAT Y, Eskandari G, Gaikwad A, Marcogliese AN, et al
Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression.
Leuk Lymphoma. 2022 Nov 8:1-6. doi: 10.1080/10428194.2022.2140285.
PubMed

DOUKAS PG, Cascino GJ, Meng Z, Baldridge AS, et al
External validation of a heart failure risk score in patients with acute myeloid leukemia.
Leuk Lymphoma. 2022 Nov 4:1-9. doi: 10.1080/10428194.2022.2140289.
PubMed Abstract available

BALL S, Loghavi S, Zeidan AM
TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.
Leuk Lymphoma. 2022 Nov 2:1-11. doi: 10.1080/10428194.2022.2136969.
PubMed Abstract available

AHMED M, Pollyea DA
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges.
Leuk Lymphoma. 2022 Nov 2:1-5. doi: 10.1080/10428194.2022.2136960.
PubMed Abstract available

ZHANG X, Tu Y, Shen J, Feng Y, et al
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study.
Leuk Lymphoma. 2022;63:2636-2644.
PubMed Abstract available

CHANDHOK NS, Sekeres MA
What constitutes meaningful improvement in myelodysplastic syndromes?
Leuk Lymphoma. 2022;63:2528-2535.
PubMed Abstract available

CHEN Y, Buhlinger K, Perissinotti AJ, Schepers AJ, et al
Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Leuk Lymphoma. 2022;63:2663-2670.
PubMed Abstract available

October 2022

BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Leuk Lymphoma. 2022 Oct 26:1-9. doi: 10.1080/10428194.2022.2136952.
PubMed Abstract available

SHAHZAD M, Chaudhary SG, Tariq E, Mushtaq AH, et al
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
Leuk Lymphoma. 2022 Oct 25:1-10. doi: 10.1080/10428194.2022.2136947.
PubMed Abstract available

HELFGOTT DC, Racine-Brzostek S, Short KJ, Zhao Z, et al
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.
Leuk Lymphoma. 2022 Oct 25:1-9. doi: 10.1080/10428194.2022.2131414.
PubMed Abstract available

GALLON R, Phelps R, Betts L, Hayes C, et al
Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Oct 22:1-4. doi: 10.1080/10428194.2022.2131412.
PubMed

WANG KY, Shah P, Skavla B, Fayaaz F, et al
Vaccination efficacy in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Oct 21:1-15. doi: 10.1080/10428194.2022.2133538.
PubMed Abstract available

OTHUS M, Thomas I, Wang X, Ariti C, et al
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Leuk Lymphoma. 2022 Oct 13:1-3. doi: 10.1080/10428194.2022.2131416.
PubMed

OYAMA T, Matsuda K, Honda A, Yasunaga M, et al
Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Leuk Lymphoma. 2022 Oct 12:1-4. doi: 10.1080/10428194.2022.2131421.
PubMed

AQIL B, Gao J, Rahn HR, Sukhanova M, et al
Non-leukemic presentation of acute promyelocytic leukemia as a testicular mass with associated non-canonical FLT3 mutation.
Leuk Lymphoma. 2022 Oct 10:1-4. doi: 10.1080/10428194.2022.2131425.
PubMed

PAULUS A, Malavasi F, Chanan-Khan A
CD38 as a multifaceted immunotherapeutic target in CLL.
Leuk Lymphoma. 2022;63:2265-2275.
PubMed Abstract available

USTUN C, Warlick E, Nathan S, Burns LJ, et al
Transplantation provides superior survival high risk myeloid malignancies in older patients.
Leuk Lymphoma. 2022;63:2494-2498.
PubMed

ENGVALL M, Karlsson Y, Kuchinskaya E, Jornegren A, et al
Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium.
Leuk Lymphoma. 2022;63:2311-2320.
PubMed Abstract available

September 2022

ISHITSUKA K, Yoshizawa Y, Nishikii H, Kusakabe M, et al
Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation.
Leuk Lymphoma. 2022 Sep 20:1-5. doi: 10.1080/10428194.2022.2123235.
PubMed

SIMON F, Giza A, Robrecht S, Fink AM, et al
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.
Leuk Lymphoma. 2022 Sep 18:1-8. doi: 10.1080/10428194.2022.2123223.
PubMed Abstract available

SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
PubMed Abstract available

LIU X, Zou Y, Zhang L, Zhang Y, et al
Characteristics and prognosis of children with recurrent T-cell acute lymphoblastic leukemia: a long-term follow-up report in China.
Leuk Lymphoma. 2022 Sep 15:1-13. doi: 10.1080/10428194.2022.2123224.
PubMed Abstract available

ZAINALDIN C, Arora S, Bathini S, Gupta U, et al
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
Leuk Lymphoma. 2022 Sep 15:1-4. doi: 10.1080/10428194.2022.2113530.
PubMed

BEHDAD A, Schipma MJ, Ma S, Chen YH, et al
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10.
Leuk Lymphoma. 2022 Sep 14:1-5. doi: 10.1080/10428194.2022.2123236.
PubMed

MUKAE J, Sadato D, Toya T, Watanabe S, et al
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Sep 14:1-4. doi: 10.1080/10428194.2022.2116936.
PubMed

EDAHIRO T, Ureshino H, Chishaki R, Fujino K, et al
Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
Leuk Lymphoma. 2022 Sep 13:1-2. doi: 10.1080/10428194.2022.2123230.
PubMed

CAI Z, Liu Y, Tang B, Wu Z, et al
Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Sep 13:1-10. doi: 10.1080/10428194.2022.2115841.
PubMed Abstract available

BALL BJ, Arslan S, Koller P, Ngo D, et al
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Leuk Lymphoma. 2022 Sep 10:1-5. doi: 10.1080/10428194.2022.2116934.
PubMed

PATIL P, Toprak UH, Seufert J, Braun T, et al
Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia.
Leuk Lymphoma. 2022 Sep 9:1-4. doi: 10.1080/10428194.2022.2116933.
PubMed

ANDRITSOS LA, Anghelina M, Neal J, Blachly JS, et al
Development of a distributed international patient data registry for hairy cell leukemia.
Leuk Lymphoma. 2022 Sep 7:1-11. doi: 10.1080/10428194.2022.2109157.
PubMed Abstract available

NAGATA A, Otsuka Y, Konuma R, Adachi H, et al
Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission.
Leuk Lymphoma. 2022 Sep 6:1-11. doi: 10.1080/10428194.2022.2109334.
PubMed Abstract available

TIBOUT P, Ledjiar O, Athale U, Rayar M, et al
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.
Leuk Lymphoma. 2022 Sep 6:1-9. doi: 10.1080/10428194.2022.2118536.
PubMed Abstract available

LU Y, Sun RJ, Zhang JP, Xu F, et al
Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
PubMed Abstract available

WEI Y, Zheng H, Lockyer PP, Darbaniyan F, et al
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leuk Lymphoma. 2022 Sep 5:1-11. doi: 10.1080/10428194.2022.2116932.
PubMed Abstract available

DURINIKOVA A, Folta A, Pardy F, Svaton J, et al
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
Leuk Lymphoma. 2022 Sep 1:1-4. doi: 10.1080/10428194.2022.2116931.
PubMed

GAGNON MF, Smadbeck JB, Sharma N, Blackburn PR, et al
Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL.
Leuk Lymphoma. 2022;63:2243-2246.
PubMed

MCCAY J, Gribben JG
The role of BTK inhibitors on the tumor microenvironment in CLL.
Leuk Lymphoma. 2022;63:2023-2032.
PubMed Abstract available

August 2022

COSTA DFD, Filiu-Braga LDC, Silva-Carvalho AE, Schiavinato JL, et al
Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Aug 25:1-5. doi: 10.1080/10428194.2022.2116935.
PubMed

LALAYANNI C, Demosthenous C, Iskas M, Kelaidi C, et al
Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
Leuk Lymphoma. 2022 Aug 24:1-10. doi: 10.1080/10428194.2022.2113527.
PubMed Abstract available

NAMJOSHI NS, Keegan THM, Li QC, Chung JH, et al
Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis.
Leuk Lymphoma. 2022 Aug 23:1-9. doi: 10.1080/10428194.2022.2113533.
PubMed Abstract available

ZAK T, Gao J, Behdad A, Mehta J, et al
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
Leuk Lymphoma. 2022 Aug 22:1-8. doi: 10.1080/10428194.2022.2113524.
PubMed Abstract available

SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
PubMed Abstract available

PERAGINE N, De Propris MS, Intoppa S, Milani ML, et al
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105324.
PubMed

TESTI AM, Al-Jadiry MF, Ghali HH, Fadhil SA, et al
Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.
Leuk Lymphoma. 2022 Aug 1:1-8. doi: 10.1080/10428194.2022.2105328.
PubMed Abstract available

SRINIVASAN S
Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
Leuk Lymphoma. 2022 Aug 1:1-3. doi: 10.1080/10428194.2022.2105327.
PubMed

BASSIG BA, Hu W, Morton LM, Ji BT, et al
Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
Leuk Lymphoma. 2022;63:1917-1924.
PubMed Abstract available

MACARON W, Sargsyan Z, Short NJ
Hyperleukocytosis and leukostasis in acute and chronic leukemias.
Leuk Lymphoma. 2022;63:1780-1791.
PubMed Abstract available

CHEN EC, Liu Y, Harris CE, Winer ES, et al
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Leuk Lymphoma. 2022;63:1934-1941.
PubMed Abstract available

COZAD M, Stump SE, Buhlinger K, Collins J 4th, et al
Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
Leuk Lymphoma. 2022;63:1831-1838.
PubMed Abstract available

July 2022

DHARIA P, Swartz MD, Bernhardt MB, Chen H, et al
Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Jul 27:1-7. doi: 10.1080/10428194.2022.2102621.
PubMed Abstract available

KUSS B, Nagarajan C, Hsieh WS, Cheah CY, et al
Practical management of chronic lymphocytic leukemia with acalabrutinib.
Leuk Lymphoma. 2022 Jul 19:1-10. doi: 10.1080/10428194.2022.2098289.
PubMed Abstract available

DAVER N, Jonas BA, Medeiros BC, Patil U, et al
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
Leuk Lymphoma. 2022 Jul 14:1-4. doi: 10.1080/10428194.2022.2092853.
PubMed

YAN W, Fan H, Xu J, Liu J, et al
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
Leuk Lymphoma. 2022 Jul 12:1-10. doi: 10.1080/10428194.2022.2098290.
PubMed Abstract available

KLINGLER F, Alsdorf WH, Ghandili S, Wolschke C, et al
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Leuk Lymphoma. 2022 Jul 5:1-7. doi: 10.1080/10428194.2022.2092855.
PubMed Abstract available

June 2022

XU Z, Yin J, Sun Q, Hu J, et al
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Leuk Lymphoma. 2022 Jun 25:1-11. doi: 10.1080/10428194.2022.2090549.
PubMed Abstract available

XU GF, Liu LM, Wang M, Zhang ZB, et al
Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
PubMed Abstract available

RAA DGT, van der Straten L, van Gelder M, Kersting S, et al
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
PubMed Abstract available

DHAKAL P, Joshi U, Lyden E, Pyakuryal A, et al
Association of insurance types and outcomes in acute promyelocytic leukemia.
Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
PubMed Abstract available

ZONG L, Xie J, Kong J, Bao X, et al
Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.
PubMed

SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
PubMed

NGO D, Otoukesh S, Stein AS, Forman S, et al
The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.
PubMed

TEDJASEPUTRA A, Kuzich JA, Thiagarajah N, Teh TC, et al
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.
PubMed

KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.
PubMed

SYMES E, Wang P, Lager AM, Bishop MR, et al
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.
PubMed

MOLICA S, Allsup DJ, Polliack A
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.
PubMed

YU G, Lu W, Chen X, Li Y, et al
Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
Leuk Lymphoma. 2022 Jun 11:1-12. doi: 10.1080/10428194.2022.2086243.
PubMed Abstract available

LYU X, Li T, Zhu D, Cheng Y, et al
Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
Leuk Lymphoma. 2022 Jun 11:1-10. doi: 10.1080/10428194.2022.2080821.
PubMed Abstract available

SABURI M, Sakata M, Takata H, Miyazaki Y, et al
Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250.
PubMed

XU J, Hao Z, Chen X, Hong M, et al
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Leuk Lymphoma. 2022 Jun 2:1-9. doi: 10.1080/10428194.2022.2081323.
PubMed Abstract available

GADAUD N, Leroy H, Berard E, Tavitian S, et al
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Leuk Lymphoma. 2022;63:1398-1406.
PubMed Abstract available

MATUTES E, Polliack A
Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
Leuk Lymphoma. 2022;63:1265-1266.
PubMed

TAHIR F, Sy J, Reddel S, Trotman J, et al
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
Leuk Lymphoma. 2022;63:1464-1468.
PubMed Abstract available

SHARPLIN KM, Marks DI
The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
Leuk Lymphoma. 2022;63:1292-1301.
PubMed Abstract available

BALL S, Komrokji RS, Sallman DA
Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
Leuk Lymphoma. 2022;63:1281-1291.
PubMed Abstract available

May 2022

MAENG CV, Christiansen CF, Liu KD, Kamper P, et al
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
Leuk Lymphoma. 2022 May 18:1-11. doi: 10.1080/10428194.2022.2074984.
PubMed Abstract available

MACHHERNDL-SPANDL S, Vockenhuber T, Binder M, Weltermann A, et al
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
Leuk Lymphoma. 2022 May 13:1-6. doi: 10.1080/10428194.2022.2068006.
PubMed Abstract available

LI Z, Peng L, Li Y, Zhang J, et al
Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
Leuk Lymphoma. 2022 May 11:1-12. doi: 10.1080/10428194.2022.2070912.
PubMed Abstract available

ASOUBAR S, Esfahani A, Vahedi A, Mohammadi SM, et al
Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
PubMed Abstract available

EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
PubMed Abstract available

SZCZEPANEK E, Chukwu O, Kaminska M, Wysoglad H, et al
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
PubMed Abstract available

PREBET T, Goldberg AD, Jurcic JG, Khaled S, et al
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
PubMed Abstract available

QIN T, Cheng Y, Wang X
RNA-binding proteins as drivers of AML and novel therapeutic targets.
Leuk Lymphoma. 2022;63:1045-1057.
PubMed Abstract available

SAUMELL S, Fernandez-Serrano M, Mesa A, Lopez-Cadenas F, et al
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
Leuk Lymphoma. 2022;63:1227-1235.
PubMed Abstract available

LI J, Liao D, Wang F, Wang Z, et al
RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.
Leuk Lymphoma. 2022;63:1167-1179.
PubMed Abstract available

April 2022

QI D, Wang J, Zhao Y, Yang Y, et al
JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia.
Leuk Lymphoma. 2022 Apr 25:1-12. doi: 10.1080/10428194.2022.2068004.
PubMed Abstract available

LI Q, Liang C, Xu X, Zhang C, et al
CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
Leuk Lymphoma. 2022 Apr 23:1-13. doi: 10.1080/10428194.2022.2064986.
PubMed Abstract available

PHAM TM, Quy PN, Amin K, Walker E, et al
Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
PubMed Abstract available

PETROV D, Timilshina N, Papadopoulos E, Alibhai SMH, et al
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive chemotherapy.
Leuk Lymphoma. 2022 Apr 22:1-8. doi: 10.1080/10428194.2022.2064993.
PubMed Abstract available

MEMOLI M, Genthon A, Favale F, Lapusan S, et al
Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study.
Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2064987.
PubMed Abstract available

SHORT NJ, Borthakur G, Pemmaraju N, Dinardo CD, et al
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Leuk Lymphoma. 2022 Apr 20:1-10. doi: 10.1080/10428194.2022.2062345.
PubMed Abstract available

NAKASE K, Tanaka I, Tawara I, Shiku H, et al
CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor alpha-chain (CD25) expression and poor prognosis.
Leuk Lymphoma. 2022 Apr 20:1-3. doi: 10.1080/10428194.2022.2062346.
PubMed

XUE S, Huang W, Liu F, Zhang Y, et al
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.
Leuk Lymphoma. 2022 Apr 19:1-4. doi: 10.1080/10428194.2022.2064994.
PubMed

MIRANTI E, Ho DY, Enriquez K, Subramanian AK, et al
Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
Leuk Lymphoma. 2022 Apr 12:1-7. doi: 10.1080/10428194.2022.2060504.
PubMed Abstract available

MANGAONKAR AA, Patnaik MM
Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation.
Leuk Lymphoma. 2022 Apr 4:1-9. doi: 10.1080/10428194.2022.2056175.
PubMed Abstract available

MINDIOLA ROMERO AE, Johnston MA, Giffin JT, Khan WA, et al
SNP-based chromosomal microarray characterization in a series of pure erythroid leukemia.
Leuk Lymphoma. 2022 Apr 3:1-4. doi: 10.1080/10428194.2022.2057489.
PubMed

FERNANDEZ A, Perez-Martinez A, Escudero A, Mirones I, et al
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Leuk Lymphoma. 2022 Apr 3:1-5. doi: 10.1080/10428194.2022.2057490.
PubMed

HADDAD F, Kantarjian H, Issa GC, Jabbour E, et al
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
Leuk Lymphoma. 2022 Apr 1:1-4. doi: 10.1080/10428194.2022.2045599.
PubMed

MIYAMOTO T, Sanford D, Tomuleasa C, Hsiao HH, et al
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy().
Leuk Lymphoma. 2022;63:928-938.
PubMed Abstract available

March 2022

KIERDORF F, Zimmer P, Joisten N, Kiesl D, et al
L-kynurenine as a prognostic marker for early mortality in patients with acute myeloid leukemia.
Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053534.
PubMed

OCHS MA, Marini BL, Benitez LL, Stump SE, et al
Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Mar 28:1-10. doi: 10.1080/10428194.2022.2053530.
PubMed Abstract available

PERKINS B, Showel M, Schoch L, Imus PH, et al
CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
PubMed Abstract available

DEODATO M, Frustaci AM, Sportoletti P, Laurenti L, et al
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053532.
PubMed

LIPTON NJ, Lipton JH
Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.
Leuk Lymphoma. 2022 Mar 25:1-2. doi: 10.1080/10428194.2022.2056180.
PubMed

GHOSH S, Roth J, Babushok D, Lim M, et al
Significance of RUNX1 mutation in BCR-ABL1 positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.
Leuk Lymphoma. 2022 Mar 15:1-5. doi: 10.1080/10428194.2022.2047673.
PubMed

GRAVENO ME, Carulli A, Freyer CW, Mangan BL, et al
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Leuk Lymphoma. 2022 Mar 8:1-6. doi: 10.1080/10428194.2022.2042688.
PubMed Abstract available

TETTAMANTI S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, et al
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299.
PubMed Abstract available

XIE W, Raess PW, Dunlap J, Hoyos CM, et al
Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome.
Leuk Lymphoma. 2022 Mar 8:1-10. doi: 10.1080/10428194.2022.2047672.
PubMed Abstract available

COLLARD JP, McKenna MK, Noothi SK, Alhakeem SS, et al
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Emicro-TCL1 transgenic mice.
Leuk Lymphoma. 2022 Mar 8:1-13. doi: 10.1080/10428194.2022.2045596.
PubMed Abstract available

ESHIBONA N, Giwa A, Rossouw SC, Gamieldien J, et al
Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation.
Leuk Lymphoma. 2022 Mar 6:1-10. doi: 10.1080/10428194.2022.2045594.
PubMed Abstract available

COLLINS J 4TH, Stump SE, Heiling H, Muir M, et al
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Mar 6:1-8. doi: 10.1080/10428194.2022.2045597.
PubMed Abstract available

GUPTA DG, Varma N, Kumar A, Naseem S, et al
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients.
Leuk Lymphoma. 2022;63:633-643.
PubMed Abstract available

BENDIG S, Stengel A, Walter W, Meggendorfer M, et al
Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients.
Leuk Lymphoma. 2022;63:747-750.
PubMed

February 2022

FU W, Huang A, Xu L, Peng Y, et al
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.
Leuk Lymphoma. 2022 Feb 28:1-8. doi: 10.1080/10428194.2022.2045600.
PubMed Abstract available

SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
PubMed Abstract available

MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
PubMed Abstract available

MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.
PubMed

VALDEZ BC, Yuan B, Murray D, Nieto Y, et al
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
Leuk Lymphoma. 2022 Feb 20:1-11. doi: 10.1080/10428194.2022.2042689.
PubMed Abstract available

KAUMEYER B, Fidai S, Sukhanova M, Yap KL, et al
MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
Leuk Lymphoma. 2022 Feb 16:1-9. doi: 10.1080/10428194.2022.2025797.
PubMed Abstract available

NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
PubMed Abstract available

KOCHNEVA CAPITAL O, CYRILLICL, Kislova M, Zhelnova EI, Petrenko AA, et al
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2022.2034157.
PubMed Abstract available

AKHTAR OS, Groman A, Singh A, Ghione P, et al
Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2021.2012662.
PubMed Abstract available

FAZIO F, Cunsolo G, Mancini F, De Propris MS, et al
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Feb 8:1-3. doi: 10.1080/10428194.2022.2032035.
PubMed

YUAN Y, Li J, Xue TL, Hu HR, et al
Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol.
Leuk Lymphoma. 2022 Feb 6:1-10. doi: 10.1080/10428194.2022.2032033.
PubMed Abstract available

SHALLIS RM, Gore SD
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034156.
PubMed Abstract available

RAMALINGAM TR, Mohanraj S, Muthu A, Prabhakar V, et al
Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.
Leuk Lymphoma. 2022;63:377-384.
PubMed Abstract available

January 2022

ROY T, An JB, Doucette K, Chappell AM, et al
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
Leuk Lymphoma. 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.
PubMed

AMREIN P, Ballen K, Stevenson K, Brunner A, et al
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Leuk Lymphoma. 2022 Jan 25:1-8. doi: 10.1080/10428194.2021.2018582.
PubMed Abstract available

CHAUDHARY S, Ganguly S, Singh A, Palanichamy JK, et al
Mitochondrial biogenesis gene POLG correlates with outcome in pediatric acute myeloid leukemia.
Leuk Lymphoma. 2022 Jan 25:1-4. doi: 10.1080/10428194.2021.2010063.
PubMed

WANG SSY
Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
PubMed Abstract available

MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
PubMed Abstract available

BURGER JA, Robak T, Demirkan F, Bairey O, et al
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
PubMed Abstract available

SASAKI K, Kantarjian H, Jabbour E
Prediction for sustained deep molecular response for treatment-free remission.
Leuk Lymphoma. 2022;63:5-6.
PubMed

WILSON NR, Bover L, Konopleva M, Han L, et al
CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
Leuk Lymphoma. 2022;63:19-30.
PubMed Abstract available

HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.
Leuk Lymphoma. 2022;63:142-151.
PubMed Abstract available

EL HUSSEIN S, Hu S, Fang H, Garces S, et al
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity.
Leuk Lymphoma. 2022;63:235-238.
PubMed

December 2021

MESSORI A, Rivano M, Mengato D, Cancanelli L, et al
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Dec 31:1-4. doi: 10.1080/10428194.2021.2022141.
PubMed

ROBOZ GJ, Yee K, Verma A, Borthakur G, et al
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leuk Lymphoma. 2021 Dec 19:1-5. doi: 10.1080/10428194.2021.2012667.
PubMed

MCQUILTEN ZK, Busija L, Seymour JF, Stanworth S, et al
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
Leuk Lymphoma. 2021 Dec 17:1-8. doi: 10.1080/10428194.2021.2012664.
PubMed Abstract available

HUNTINGTON SF, Ingham MP, Okonkwo L, Singh A, et al
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
Leuk Lymphoma. 2021 Dec 16:1-11. doi: 10.1080/10428194.2021.2012666.
PubMed Abstract available

KANAGAL-SHAMANNA R, Bao H, Kearney H, Smoley S, et al
Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
Leuk Lymphoma. 2021 Dec 13:1-11. doi: 10.1080/10428194.2021.2010061.
PubMed Abstract available

CABRERA ME, Marinov N, Roa M, Castillo JJ, et al
Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile.
Leuk Lymphoma. 2021 Dec 10:1-7. doi: 10.1080/10428194.2021.2012663.
PubMed Abstract available

SALHOTRA A, Yang D, Mokhtari S, Hui S, et al
Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
Leuk Lymphoma. 2021 Dec 9:1-7. doi: 10.1080/10428194.2021.2012661.
PubMed Abstract available

SHEN X, Zhang L, Xing S, Zhang XW, et al
Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
Leuk Lymphoma. 2021 Dec 8:1-9. doi: 10.1080/10428194.2021.2008382.
PubMed Abstract available

EGELI DB, Hanfstein B, Lauseker M, Pfirrmann M, et al
SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.
Leuk Lymphoma. 2021 Dec 6:1-8. doi: 10.1080/10428194.2021.2010059.
PubMed Abstract available

BANASZAK LG, Reinig E, Lasarev MR, Mattison RJ, et al
Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
Leuk Lymphoma. 2021 Dec 6:1-10. doi: 10.1080/10428194.2021.1999435.
PubMed Abstract available

GAGEZ AL, Paul F, Alaterre E, Gouilleux-Gruart V, et al
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
Leuk Lymphoma. 2021;62:3160-3169.
PubMed Abstract available

BEWERSDORF JP, Stone RM, Tallman MS, Stahl M, et al
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
Leuk Lymphoma. 2021;62:3318-3319.
PubMed

BEWERSDORF JP, Derkach A, Gowda L, Menghrajani K, et al
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Leuk Lymphoma. 2021;62:3394-3401.
PubMed Abstract available

SMALL SH, Altman JK, Platanias LC
Interferon maintenance for prevention of relapse in favorable risk AML?
Leuk Lymphoma. 2021;62:2818-2819.
PubMed

STABER PB, Jurczak W, Greil R, Vucinic V, et al
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leuk Lymphoma. 2021;62:3440-3451.
PubMed Abstract available

LUKES J, Wolthers BO, Altaf Raja R, Uhrinova K, et al
Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis.
Leuk Lymphoma. 2021;62:3506-3510.
PubMed

LU H, Li ZY, Ding M, Liang C, et al
Trametinib enhances ATRA-induced differentiation in AML cells.
Leuk Lymphoma. 2021;62:3361-3372.
PubMed Abstract available

LOO S, Wei AH
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
Leuk Lymphoma. 2021;62:3073-3077.
PubMed

WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
Idelalisib immune-related toxicity is associated with improved treatment response.
Leuk Lymphoma. 2021;62:2915-2920.
PubMed Abstract available

MEGHEREA O, Janes C, Kowalski A, Baron J, et al
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
Leuk Lymphoma. 2021;62:3219-3225.
PubMed Abstract available

SHIMONY S, Bar-Sever E, Berger T, Itchaki G, et al
Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.
Leuk Lymphoma. 2021;62:2921-2927.
PubMed Abstract available

November 2021

PRZESPOLEWSKI AC, Portwood S, Wang ES
Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
Leuk Lymphoma. 2021 Nov 25:1-10. doi: 10.1080/10428194.2021.1992614.
PubMed Abstract available

PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
PubMed

KHANAL N, Shostrom V, Dhakal P, Upadhyay Banskota S, et al
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
Leuk Lymphoma. 2021 Nov 17:1-7. doi: 10.1080/10428194.2021.2005046.
PubMed Abstract available

YUE X, Hincapie AL, Li Y, Guo JJ, et al
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
Leuk Lymphoma. 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
PubMed Abstract available

JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
PubMed

HALPERN AB, Estey EH
More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels.
Leuk Lymphoma. 2021 Nov 8:1-4. doi: 10.1080/10428194.2021.1999446.
PubMed

ZEIDAN AM, Qi CZ, Yang H, Garnham A, et al
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Leuk Lymphoma. 2021 Nov 8:1-3. doi: 10.1080/10428194.2021.2001467.
PubMed

DA CUNHA-BANG C, Kirkby NS, Friis-Hansen L, Niemann CU, et al
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Nov 2:1-3. doi: 10.1080/10428194.2021.1973673.
PubMed

ARUMUGAM JR, Bommannan K, Radhakrishnan V, Sagar TG, et al
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Leuk Lymphoma. 2021 Nov 2:1-9. doi: 10.1080/10428194.2021.1992755.
PubMed Abstract available

RIDGE SM, Whiteley AE, Yao H, Price TT, et al
Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
Leuk Lymphoma. 2021;62:2690-2702.
PubMed Abstract available

SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
Leuk Lymphoma. 2021;62:2716-2726.
PubMed Abstract available

PATNAIK MM, Mughal TI, Brooks C, Lindsay R, et al
Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
Leuk Lymphoma. 2021;62:2568-2586.
PubMed Abstract available

October 2021

ALDOSS I, Clark M, Marcucci G, Forman SJ, et al
Donor derived leukemia in allogeneic transplantation.
Leuk Lymphoma. 2021 Oct 29:1-8. doi: 10.1080/10428194.2021.1929966.
PubMed Abstract available

REX MR, Williams R, Birsoy K, Ta Llman MS, et al
Targeting mitochondrial metabolism in acute myeloid leukemia.
Leuk Lymphoma. 2021 Oct 27:1-8. doi: 10.1080/10428194.2021.1992759.
PubMed Abstract available

GHIUZELI CM, Styblo M, Saunders J, Calabro A, et al
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Leuk Lymphoma. 2021 Oct 25:1-11. doi: 10.1080/10428194.2021.1978084.
PubMed Abstract available

TONG WH
Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'.
Leuk Lymphoma. 2021 Oct 22:1-2. doi: 10.1080/10428194.2021.1992760.
PubMed

CHEN M, Fu M, Wang A, Wu X, et al
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
Leuk Lymphoma. 2021 Oct 21:1-9. doi: 10.1080/10428194.2021.1980214.
PubMed Abstract available

GJAERDE LK, Rank CU, Andersen MK, Jakobsen LH, et al
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study.
Leuk Lymphoma. 2021 Oct 21:1-10. doi: 10.1080/10428194.2021.1992620.
PubMed Abstract available

RAMOS PEREZ JM, Patel KP, Loghavi S, Garcia-Manero G, et al
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992757.
PubMed Abstract available

DOMENECH C, Plesa A, Tourette A, Bertrand Y, et al
Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia.
Leuk Lymphoma. 2021 Oct 18:1-6. doi: 10.1080/10428194.2021.1992616.
PubMed

LI S, Ji Y, Peng Y, Kota V, et al
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
Leuk Lymphoma. 2021 Oct 13:1-11. doi: 10.1080/10428194.2021.1973669.
PubMed Abstract available

COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
Leuk Lymphoma. 2021 Oct 11:1-11. doi: 10.1080/10428194.2021.1986217.
PubMed Abstract available

AGIUS R, Parviz M, Niemann CU
Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art.
Leuk Lymphoma. 2021 Oct 6:1-14. doi: 10.1080/10428194.2021.1973672.
PubMed Abstract available

XUE S, Zhang Y, Liu F, Huang W, et al
Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation.
Leuk Lymphoma. 2021 Oct 5:1-5. doi: 10.1080/10428194.2021.1984453.
PubMed

NACHMIAS B, Rund D
p53 in Acute Myeloid Leukemia-Still a significant other.
Leuk Lymphoma. 2021 Oct 5:1-3. doi: 10.1080/10428194.2021.1988592.
PubMed

LEE Y, Yun J, Jeong D, Ryu S, et al
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Leuk Lymphoma. 2021 Oct 1:1-10. doi: 10.1080/10428194.2021.1983568.
PubMed Abstract available

SEYMOUR JF
The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
Leuk Lymphoma. 2021;62:2299-2302.
PubMed

ALHALLAK K, de la Puente P, Jeske A, Sun J, et al
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Leuk Lymphoma. 2021;62:2457-2465.
PubMed Abstract available

JACOBY MA, Finn L, Emadi A, Saba NS, et al
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
Leuk Lymphoma. 2021;62:2539-2542.
PubMed

RAMAN I, Pasricha SR, Prince HM, Yannakou CK, et al
Management of hydroxyurea resistant or intolerant polycythemia vera.
Leuk Lymphoma. 2021;62:2310-2319.
PubMed Abstract available

SHIMONY S, Yeshurun M, Wolach O, Ram R, et al
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
Leuk Lymphoma. 2021;62:2475-2481.
PubMed Abstract available

September 2021

VAN BESIEN K, Gomez-Arteaga A
Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
Leuk Lymphoma. 2021 Sep 29:1-4. doi: 10.1080/10428194.2021.1980787.
PubMed

MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
PubMed Abstract available

CHAJUWAN T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C, et al
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984454.
PubMed Abstract available

ALDERUCCIO JP, Lossos IS
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
PubMed Abstract available

STAHL M, Tallman MS, Goldberg AD
Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.
Leuk Lymphoma. 2021 Sep 14:1-2. doi: 10.1080/10428194.2021.1929967.
PubMed

PATEL SA, Lloyd MR, Cerny J, Shi Q, et al
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.
Leuk Lymphoma. 2021 Sep 9:1-13. doi: 10.1080/10428194.2021.1957869.
PubMed Abstract available

BANKAR A, Lipton JH
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
Leuk Lymphoma. 2021 Sep 8:1-10. doi: 10.1080/10428194.2021.1971219.
PubMed Abstract available

KHULLAR K, Plascak JJ, Parikh RR
Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility.
Leuk Lymphoma. 2021 Sep 8:1-9. doi: 10.1080/10428194.2021.1975187.
PubMed Abstract available

JACOBS JW, Ramaswamy R, States V, Reppucci J, et al
Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
Leuk Lymphoma. 2021 Sep 6:1-5. doi: 10.1080/10428194.2021.1975191.
PubMed Abstract available

XU DM, Yu WJ, Xie L, Zhang ZW, et al
The diagnostic profile of rare acute myelomegakaryoblastic leukemia.
Leuk Lymphoma. 2021 Sep 3:1-8. doi: 10.1080/10428194.2021.1955878.
PubMed Abstract available

VENUGOPAL S, Maiti A, DiNardo CD, Qiao W, et al
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Leuk Lymphoma. 2021 Sep 3:1-5. doi: 10.1080/10428194.2021.1973675.
PubMed

DUPUY H, Dussiau C, Bidet A, Sauvezie M, et al
Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
Leuk Lymphoma. 2021 Sep 3:1-3. doi: 10.1080/10428194.2021.1973674.
PubMed

FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
Leuk Lymphoma. 2021;62:2295-2297.
PubMed

ELITZUR S, Frank S, Goshen-Lago T, Barzilai-Birenboim S, et al
Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia.
Leuk Lymphoma. 2021;62:2211-2218.
PubMed Abstract available

DE CARVALHO AC, Ogawa CY Junior, De Camillis Rodrigues L, de Medeiros LS, et al
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
Leuk Lymphoma. 2021;62:2079-2093.
PubMed Abstract available

PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.
Leuk Lymphoma. 2021;62:2261-2266.
PubMed Abstract available

ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Leuk Lymphoma. 2021;62:2292-2294.
PubMed

August 2021

HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.
PubMed

PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
PubMed Abstract available

ZERBIT J, Tamburini J, Goldwirt L, Decroocq J, et al
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Aug 18:1-4. doi: 10.1080/10428194.2021.1966787.
PubMed

WANG J, Yang L, Dao FT, Wang YZ, et al
Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
PubMed Abstract available

KIMBLE EL, Cassaday RD
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
Leuk Lymphoma. 2021 Aug 17:1-15. doi: 10.1080/10428194.2021.1964022.
PubMed Abstract available

SOREL N, Raimbault A, Brizard F, Depaire T, et al
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia.
Leuk Lymphoma. 2021 Aug 17:1-5. doi: 10.1080/10428194.2021.1966784.
PubMed

MITROVIC M, Pantic N, Sabljic N, Vucic M, et al
Acute leukemia and SARS-CoV-2 infection: clinical characteristics and risk factors for mortality.
Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1964026.
PubMed Abstract available

WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.
PubMed

ABBAS HA, Reville PK, Geppner A, Rausch CR, et al
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
Leuk Lymphoma. 2021 Aug 12:1-9. doi: 10.1080/10428194.2021.1961235.
PubMed Abstract available

NEE A, Lipton JH, Kim DDH
Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.
Leuk Lymphoma. 2021 Aug 11:1-8. doi: 10.1080/10428194.2021.1961234.
PubMed Abstract available

CORDOVA-SERRANO RD, Almanza-Huante E, Fernandez-Sanchez E, Hernandez-Alcantara A, et al
Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry.
Leuk Lymphoma. 2021 Aug 9:1-7. doi: 10.1080/10428194.2021.1957872.
PubMed Abstract available

KUTTIKRISHNAN S, Prabhu KS, Khan AQ, Alali FQ, et al
Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.
Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957873.
PubMed Abstract available

AL-HADAD SA, Al-Jadiry MF, Ghali HH, Al-Badri SAF, et al
Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center.
Leuk Lymphoma. 2021 Aug 6:1-10. doi: 10.1080/10428194.2021.1961237.
PubMed Abstract available

YANADA M, Mizuno S, Yamasaki S, Harada K, et al
Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
Leuk Lymphoma. 2021 Aug 4:1-9. doi: 10.1080/10428194.2021.1961242.
PubMed Abstract available

COPPOLA PE, Broccoli A, Argnani L, Casadei B, et al
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961241.
PubMed

RAMIREZ-LOPEZ A, Lazaro Del Campo P, Humala K, De la Cruz Benito B, et al
Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.
Leuk Lymphoma. 2021;62:2034-2036.
PubMed

ROSSO A, Juliusson G, Lorenz F, Lehmann S, et al
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
Leuk Lymphoma. 2021;62:1973-1981.
PubMed Abstract available

NAUR TMH, Jakobsen LH, Roug AS, El-Galaly TC, et al
Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study.
Leuk Lymphoma. 2021;62:2014-2017.
PubMed

July 2021

WAN CL, Zou JY, Qiao M, Yin J, et al
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957876.
PubMed

KOUTROUMANI M, Laidou S, Kotta K, Stamatopoulos K, et al
TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957870.
PubMed

SWEET K, Bhatnagar B, Dohner H, Donnellan W, et al
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706.
PubMed Abstract available

EL HUSSEIN S, Wang W, Wang SA, Loghavi S, et al
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon.
Leuk Lymphoma. 2021 Jul 24:1-4. doi: 10.1080/10428194.2021.1957878.
PubMed

PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
PubMed Abstract available

WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
PubMed Abstract available

DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
PubMed Abstract available

BEYAN C
Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia.
Leuk Lymphoma. 2021 Jul 14:1. doi: 10.1080/10428194.2021.1953017.
PubMed

GAO J, Fu L, Lu X, Sukhanova M, et al
Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity.
Leuk Lymphoma. 2021 Jul 14:1-4. doi: 10.1080/10428194.2021.1950710.
PubMed

PAGNANO KB, Peralta EH, Navarro JR, David Salas LDR, et al
COVID-19 in chronic myeloid leukemia patients in Latin America.
Leuk Lymphoma. 2021 Jul 13:1-7. doi: 10.1080/10428194.2021.1950709.
PubMed Abstract available

JIANG H, Liu XH, Kong J, Wang J, et al
Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
PubMed Abstract available

JINDAL N, Lad DP, Malhotra P, Prakash G, et al
Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
Leuk Lymphoma. 2021;62:1674-1681.
PubMed Abstract available

WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
Leuk Lymphoma. 2021;62:1692-1701.
PubMed Abstract available

June 2021

STAHL M, Narendra V, Jee J, Derkach A, et al
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
PubMed Abstract available

LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
PubMed Abstract available

YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
PubMed Abstract available

SINGH J, Facey A, O'Malley F, Ryland GL, et al
Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.
PubMed

HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.
PubMed

RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.
PubMed

BOLUDA B, Martinez-Cuadron D, Algarra L, Cano I, et al
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1938031.
PubMed Abstract available

CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
Body mass index and survival of patients with lymphoma.
Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
PubMed Abstract available

KHAZAL S, Kebriaei P
Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
Leuk Lymphoma. 2021 Jun 3:1-14. doi: 10.1080/10428194.2021.1933475.
PubMed Abstract available

STUBBINS RJ, Maksakov IA, Sanford DS, Rouhi A, et al
Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
Leuk Lymphoma. 2021 Jun 1:1-11. doi: 10.1080/10428194.2021.1910685.
PubMed Abstract available

BOULLAND ML, Vic S, Thonier F, Ganard M, et al
Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Jun 1:1-4. doi: 10.1080/10428194.2021.1933476.
PubMed

LADHA A, Hui G, Cheung E, Berube C, et al
Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
Leuk Lymphoma. 2021;62:1510-1513.
PubMed

SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
Leuk Lymphoma. 2021;62:1514-1517.
PubMed

QU S, Jia Y, Wang H, Ai X, et al
STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
Leuk Lymphoma. 2021;62:1506-1509.
PubMed

May 2021

YURKIEWICZ IR, Coutre S, Ghesquieres H, Pastan I, et al
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
Leuk Lymphoma. 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.
PubMed

CUMBO C, Tota G, De Grassi A, Anelli L, et al
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.
Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929960.
PubMed

SHARMA P, Rana S, Virk H, Sachdeva MUS, et al
The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929964.
PubMed

JIN H, Zhu Y, Hong M, Wu Y, et al
Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.
Leuk Lymphoma. 2021 May 24:1-10. doi: 10.1080/10428194.2021.1919660.
PubMed Abstract available

BAZINET A, Rys RN, Barry A, Greenwood CMT, et al
A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1919658.
PubMed Abstract available

TIGLIOGLU M, Albayrak M, Dogan S, Yilmaz F, et al
Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis.
Leuk Lymphoma. 2021 May 20:1-7. doi: 10.1080/10428194.2021.1929962.
PubMed Abstract available

HANDL S, von Heydebrand F, Voelkl S, Oostendorp RAJ, et al
Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 May 17:1-11. doi: 10.1080/10428194.2021.1927019.
PubMed Abstract available

LIANG D, Wei C, Zhang X, Yang J, et al
Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
PubMed

KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
PubMed Abstract available

DAVIDS MS, Telford C, Abhyankar S, Waweru C, et al
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 May 6:1-16. doi: 10.1080/10428194.2021.1913144.
PubMed Abstract available

ADNAN-AWAD S, Kankainen M, Mustjoki S
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Leuk Lymphoma. 2021 May 4:1-15. doi: 10.1080/10428194.2021.1894652.
PubMed Abstract available

MARQUES-PIUBELLI ML, Schlette EJ, Khoury JD, Furqan F, et al
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Leuk Lymphoma. 2021;62:1129-1135.
PubMed Abstract available

April 2021

WALLWITZ J, Aigner P, Stoiber D
Tumor suppressors in acute myeloid leukemia.
Leuk Lymphoma. 2021 Apr 30:1-11. doi: 10.1080/10428194.2021.1907372.
PubMed Abstract available

WANG M, Wang R, Wang H, Chen C, et al
Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
Leuk Lymphoma. 2021 Apr 29:1-12. doi: 10.1080/10428194.2021.1919661.
PubMed Abstract available

WANG N, Yuan L, Jing Y, Fan K, et al
Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations.
Leuk Lymphoma. 2021 Apr 27:1-9. doi: 10.1080/10428194.2021.1919663.
PubMed Abstract available

REES MJ, Wu S, Mokoonlall M, Dix CHK, et al
The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Apr 26:1-3. doi: 10.1080/10428194.2021.1919666.
PubMed

ZHAN M, Chen ZB, Ding CC, Qu Q, et al
Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
Leuk Lymphoma. 2021 Apr 26:1-12. doi: 10.1080/10428194.2021.1913140.
PubMed Abstract available

GUPTA A, Gill S
CAR-T cell persistence in the treatment of leukemia and lymphoma.
Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
PubMed Abstract available

WALKER KL, Rinella SP, Hess NJ, Turicek DP, et al
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Leuk Lymphoma. 2021 Apr 11:1-11. doi: 10.1080/10428194.2021.1910684.
PubMed Abstract available

FAZIO F, Quintini M, Carmosino I, Matteucci C, et al
New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia.
Leuk Lymphoma. 2021 Apr 9:1-4. doi: 10.1080/10428194.2021.1910689.
PubMed

BENITEZ LL, Perissinotti AJ, Rausch CR, Klaus J, et al
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378.
PubMed Abstract available

PASIC I, Paulson K, Dozois G, Schultz KR, et al
Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.
Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1910688.
PubMed Abstract available

HIDALGO-GOMEZ G, Palacio-Garcia C, Gallur L, Blanco A, et al
Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
Leuk Lymphoma. 2021 Apr 7:1-9. doi: 10.1080/10428194.2021.1907375.
PubMed Abstract available

JOBSON D, McCormack CJ, Hiscutt E, Tam C, et al
Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL.
Leuk Lymphoma. 2021;62:992-994.
PubMed

HARROP S, Polliack A, Tam CS
Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
Leuk Lymphoma. 2021;62:771-778.
PubMed Abstract available

PACOUREAU L, De Menthon M, Boytchev I, Lazure T, et al
Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
Leuk Lymphoma. 2021;62:984-987.
PubMed

March 2021

CHEN NC, Borthakur G, Pemmaraju N
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
Leuk Lymphoma. 2021;62:528-537.
PubMed Abstract available

December 2020

FOX TA, Carpenter B, Taj M, Perisoglou M, et al
Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.
PubMed

November 2020

RASOR B, Dickerson T, Zhao Q, Elder P, et al
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
PubMed Abstract available

WANG T, Zhou B, Zhang J, Zhang X, et al
Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
PubMed Abstract available

PAN W, Zhao X, Shi W, Jiang Z, et al
Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
Leuk Lymphoma. 2020;61:2756-2759.
PubMed

October 2020

RODGERS TD, Williams AM, Baran A, Reagan PM, et al
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
PubMed Abstract available

August 2020

NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
PubMed Abstract available

June 2020

LU JP, Wang FX, Wen SP, Liu X, et al
Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.
PubMed

January 2020

RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.
PubMed

October 2019

KUMAR P, Uppal M, Xiao W, Dogan A, et al
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.
PubMed

September 2019

WANG F, Liu T, Wang L, Gu Z, et al
Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
PubMed Abstract available

August 2019

BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.